What is the correct anterior‑posterior (A‑P) pad placement for defibrillation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Correct Anterior-Posterior (A-P) Pad Placement for Defibrillation

For anterior-posterior (A-P) pad placement, place the anterior pad on the left side of the chest between the midline and the nipple (avoiding breast tissue in females, positioning it to the left of the lower sternum), and place the posterior pad on the left side of the patient's spine just below the scapula 1.

Standard Initial Pad Placement: Anterolateral (A-L) Position

The anterolateral (A-L) position is the recommended standard for initial defibrillation in adults 1. This positioning optimizes placement speed and minimizes interruptions to chest compressions:

  • Sternal pad: Below the right clavicle, just to the right of the upper sternal border
  • Apical pad: Center in the left midaxillary line, below the armpit (not too anterior—this is a common error) 2, 1

The A-L position should be your default approach for all initial defibrillation attempts.

When to Use Anterior-Posterior (A-P) Positioning

As an Alternative to A-L

If the initial A-L position is not feasible (e.g., anatomical constraints, surgical dressings, implanted devices), consider using the A-P position as an alternative 1.

For Refractory Ventricular Fibrillation

The most compelling evidence for A-P positioning comes from refractory VF cases. A 2024 cluster RCT demonstrated that changing to A-P pad position after 3 failed defibrillation attempts in the A-L position significantly improved survival to hospital discharge (21.7% vs 13.3%; adjusted risk ratio 1.71,95% CI 1.01-2.88) 1. This same study showed higher rates of VF termination with the vector change (79.9% vs 67.6%) 1.

For adults in refractory VF (persistent VF after 3 defibrillations), consider changing pads to the A-P position 1.

Critical Technical Details for A-P Placement

Anterior Pad Positioning

  • Place on the left side of the chest
  • Position between the midline of the chest and the nipple
  • For female patients: Place to the left of the lower sternum, avoiding breast tissue as much as possible 1

Posterior Pad Positioning

  • Place on the left side of the patient's spine
  • Position just below the scapula (left infrascapular region) 1
  • Note: Research shows no difference in transthoracic impedance whether the posterior pad is placed in the right or left infrascapular position 3, but current guidelines specify left-sided placement

Important Caveats and Common Pitfalls

Pad Contact and Breast Tissue

  • Always avoid breast tissue when placing pads 1
  • Ensure direct skin contact—use pregelled pads or electrolyte gel 2
  • Evidence suggests it may be possible to place pads by adjusting bra positioning rather than removing it entirely, with no adverse events observed even over metal underwires 2

Placement Accuracy Issues

Research reveals a significant problem: even trained ALS instructors frequently misplace defibrillation pads, with only 18-32% achieving correct placement in various positions 4. The apical pad in A-L positioning is commonly placed too far caudal (78mm below optimal) and too medial (59mm from optimal) 5. This underscores the need for careful attention to anatomical landmarks.

A-P Position Limitations

The A-P position is not feasible with paddles (only with adhesive pads) 1. This is relevant in some low-resource settings where paddles may still be in use.

Evidence Quality and Strength

The recommendations are based primarily on 2025 ILCOR and AHA guidelines 1, which represent the most current international consensus. However, the certainty of evidence is very low for comparing different pad positions in initial defibrillation, as no high-quality studies have compared A-L versus A-P positioning for first shocks on patient outcomes 1.

The strongest evidence (moderate quality, single RCT) supports A-P positioning specifically for refractory VF after 3 failed shocks, showing improved survival 1, 6. This represents a significant advancement in the 2025 guidelines.

Transthoracic Impedance

All three AHA-recommended positions (anterior-apex, apex-posterior, anterior-posterior) have equivalent transthoracic impedance and should theoretically deliver similar current flow 3. The survival benefit seen with A-P positioning in refractory VF likely relates to changing the electrical vector rather than impedance differences.

References

Related Questions

A 68-year-old white male, 21 days post total hip arthroplasty, has itching at the clean, dry surgical site without drainage; what measures can be taken to resolve or minimize the itching?
In a 79-year-old patient receiving enteral tube feeding who presents with diarrhea, which stool test should be ordered first?
In a 55‑year‑old man with a recent electrocardiogram showing sinus rhythm, a QS complex in V1, poor R‑wave progression in V2, left‑atrial enlargement, and a prolonged QT interval, what is the most likely diagnosis and appropriate treatment?
How do I convert an infusion rate of 60 cc per hour to drops per minute using a microdrip set?
What is the appropriate evaluation and management for an 82‑year‑old male presenting with lower abdominal pain and a burning sensation on urination?
How should cystitis presenting with flank pain and chills be treated?
In a patient with a history of postural orthostatic tachycardia syndrome (POTS) and insomnia, what medication(s) are appropriate for treating the insomnia?
What is the natural progression of pes planus (flatfoot) across childhood, adolescence, and adulthood?
For an adult patient without specific contraindications, which medication—vortioxetine or sertraline—provides better long‑term safety, psychiatric stability, and side‑effect profile?
Is it safe to perform a cardiac stress test on a patient with an abdominal aortic aneurysm (AAA)?
In a 17-year-old female using Yasmin (ethinyl estradiol 30 µg/drospirenone 3 mg) 28‑day combined oral contraceptive who experiences mid‑cycle breakthrough bleeding and fails to have withdrawal bleeding during the placebo week, what is the next best management step?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.